The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis

Acute myeloid leukemia (AML) is an aggressive stem cell malignancy that is difficult to treat. There are limitations to the current treatment regimes especially after disease relapse, and therefore new therapeutic agents are urgently required which can overcome drug resistance whilst avoiding unnece...

Descripción completa

Detalles Bibliográficos
Autores principales: van Dijk, Marianne, Murphy, Eoin, Morrell, Ruth, Knapper, Steven, O'Dwyer, Michael, Samali, Afshin, Szegezdi, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756416/
https://www.ncbi.nlm.nih.gov/pubmed/24212664
http://dx.doi.org/10.3390/cancers3011329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756416/
https://www.ncbi.nlm.nih.gov/pubmed/24212664
http://dx.doi.org/10.3390/cancers3011329

Ejemplares similares